Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Risk Assessment

View and export this data going back to 2006. Start your Free Trial

What is Catalyst Pharmaceuticals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Catalyst Pharmaceuticals is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Catalyst Pharmaceuticals's Risk Assessment

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Catalyst Pharmaceuticals's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Risk Assessment falls into.

Catalyst Pharmaceuticals (NAS:CPRX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Catalyst Pharmaceuticals Risk Assessment Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

CN2:Germany

Address

355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134

Website

https://www.catalystpharma.com

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Executives

Molly Harper	director	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Alicia Grande	officer: Chief Accounting Officer	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Gary Ingenito	officer: Chief Medical Officer	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Steve Miller	officer: VP Development & Management	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Patrick J Mcenany	director, 10 percent owner, officer: President and Chief Executive	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Carmen Jeffrey Del	officer: Chief Commercial Officer	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd	officer: Chief Compliance/Legal Officer	355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Philip H Coelho	director	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe	director	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Donald A Denkhaus	director	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Preethi Sundaram	officer: Chief Product Devel. Officer	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Daniel Brennan	officer: Chief Commercial Officer	C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286
M Douglas Winship	officer: V.P. of Regulatory Operations	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134